OXYLONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OXYLONE (OXYLONE).
Corticosteroid that binds to glucocorticoid receptors, modulating transcription of anti-inflammatory proteins and suppressing immune response.
| Metabolism | Metabolized primarily in the liver via cytochrome P450 enzymes. |
| Excretion | Renal: 70-90% (as metabolites, mainly 6β-hydroxycortisol and other conjugates); Biliary/fecal: <10%; Unchanged drug: <5% in urine. |
| Half-life | Terminal elimination half-life: 1.5-2.5 hours. Clinical context: Short half-life necessitates multiple daily dosing for sustained anti-inflammatory effect; accumulation minimal with repeated dosing. |
| Protein binding | Corticosteroid-binding globulin (CBG) 90-95%; Albumin 5-10%; total bound 95-98%. |
| Volume of Distribution | 0.4-0.6 L/kg. Clinical meaning: Moderate distribution consistent with high protein binding; does not extensively distribute into tissues. |
| Bioavailability | Oral: 70-90% (due to extensive first-pass metabolism in liver); Topical: 1-5% (varies with skin condition and formulation); Intramuscular: 100%; Intravenous: 100%. |
| Onset of Action | Oral: 2-4 hours; Topical: 1-2 hours; Intramuscular: 4-6 hours; Intravenous: immediate (within minutes). |
| Duration of Action | Oral: 30-36 hours (clinical duration due to delayed receptor-mediated effects); Topical: 8-12 hours per application; Intramuscular: 24-48 hours; Intravenous: 12-24 hours. Note: Duration longer than half-life due to intracellular persistence. |
| Molecular Weight | 376.46 |
Apply topically to affected area twice daily.
| Dosage form | CREAM |
| Renal impairment | No adjustment required as systemic absorption is minimal. |
| Liver impairment | No adjustment required as systemic absorption is minimal. |
| Pediatric use | Use smallest amount for shortest duration; avoid prolonged use. |
| Geriatric use | Use with caution; skin thinning and increased systemic absorption risk. |
| 1st trimester | Avoid. Corticosteroids are associated with cleft palate (first trimester) in animal studies; human data are limited but suggest a small increased risk of oral clefts. |
| 2nd trimester | Caution. Use only if clearly needed; may cause fetal growth restriction, adrenal suppression, or other adverse effects with prolonged use. |
| 3rd trimester | Caution. May suppress neonatal adrenal function; risk of intrauterine growth restriction with prolonged use. Use lowest effective dose. |
Clinical note
Comprehensive clinical and safety monograph for OXYLONE (OXYLONE).
| Placental transfer | Corticosteroids cross the placenta; fluorinated compounds like dexamethasone (similar potency) have higher placental transfer. Oxylone (fluorometholone) as a topical agent likely has minimal systemic absorption and thus negligible placental transfer when used appropriately. |
| Breastfeeding | Systemic corticosteroids enter breast milk in small amounts (typically <10% of maternal dose). Theoretical risks include growth suppression and endogenous corticosteroid suppression in infants. Use lowest effective dose for shortest duration; consider four-hour delay after oral dosing to minimize infant exposure. Ophthalmic use is considered compatible with breastfeeding. |
■ FDA Black Box Warning
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
| Serious Effects |
Hypersensitivity to fluorometholone or any component of the formulationUntreated ocular infections (bacterial, fungal, viral, mycobacterial)Epithelial herpes simplex keratitis (dendritic keratitis)Fungal diseases of ocular structuresVaricella or vaccinia infection of the eye
| Precautions | HPA axis suppression with prolonged use, especially in children and with occlusive dressings, Local adverse reactions including atrophy, striae, and telangiectasias, Potential for systemic effects if used on large areas or under occlusion, Use with caution in patients with skin infections |
| Food/Dietary | No significant food interactions reported with topical use. Systemic absorption is minimal, so no dietary restrictions are necessary. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Oxylone (fluorometholone) is a corticosteroid. In the first trimester, systemic corticosteroids are associated with a small increased risk of cleft palate. Second and third trimester exposure may increase risk of intrauterine growth restriction and adrenal insufficiency in the neonate. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor for signs of adrenal suppression in mother and neonate if systemic exposure. In prolonged use, assess for intrauterine growth restriction via ultrasound. Monitor neonatal cortisol levels if maternal systemic exposure near term. |
| Fertility Effects | No specific human studies; animal studies show no effect on fertility with fluorometholone. Systemic corticosteroids may alter menstrual cycle and sperm count at high doses; clinical significance unknown. |
| Clinical Pearls | Oxylone is a high-potency topical corticosteroid; limit use to short courses (≤2 weeks) on non‑intertriginous areas. Avoid use on face, groin, or axillae due to risk of skin atrophy. Monitor for systemic absorption if used over large surface areas or under occlusion. Taper upon discontinuation to avoid rebound. |
| Patient Advice | Apply a thin layer only to affected skin areas; avoid contact with eyes, mouth, and mucous membranes. · Do not wrap, cover, or bandage the treated area unless directed by your healthcare provider. · Use for the shortest duration necessary; prolonged use can cause skin thinning, stretch marks, and other side effects. · Wash hands after application unless treating the hands. · Do not use for conditions other than prescribed; avoid using on broken or infected skin. |